RIL
CHRS icon

Rothschild Investment LLC’s Coherus Oncology CHRS Stock Holding History

Rothschild Investment LLC’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286 Buy
204
+16
+9% +$26 ﹤0.01% 3379
2026
Q1 		$318 Buy
188
+129
+219% +$229 ﹤0.01% 3221
2025
Q4 		$84 Buy
+59
New +$86 ﹤0.01% 3225
2024
Q4 		– Sell
-95
Closed -$99 – 2975
2024
Q3 		$99 Buy
95
+30
+46% +$41 ﹤0.01% 2849
2024
Q2 		$112 Buy
+65
New +$131 ﹤0.01% 2704

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Rothschild Investment LLC's CHRS Position: Q2 2026 in Review

Rothschild Investment LLC increased its Coherus Oncology (CHRS) stake by 8.5% in Q2 2026, buying an estimated $26 and bringing the position to 204 shares worth $286. The position accounts for ﹤0.01% of the portfolio, ranked #3379.

Rothschild Investment LLC first reported a position in CHRS in Q2 2024 and has held it in 5 quarters since. The position peaked at $318 in Q1 2026. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Rothschild Investment LLC held 204 shares of Coherus Oncology worth $286 as of Q2 2026.
  • Rothschild Investment LLC bought 16 Coherus Oncology shares in Q2 2026, an estimated $26.
  • Coherus Oncology made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3379 holding.
  • Rothschild Investment LLC first reported a position in Coherus Oncology in Q2 2024 and has held it in 5 quarters since.
  • Rothschild Investment LLC's Coherus Oncology position peaked at $318 in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.